Clinical Trial Search

Primary: Percentage of Healthy Participants Reporting Mild-to-Moderate Influenza Disease (MMID) by Baseline A/Bethesda/MM2/H1N1 Hemagglutination Inhibition (HAI) Antibody…

Primary: Percent MMID — 0; 0; 20; 47 percentage of participants

Primary: Serum Haemagglutination-inhibition (HI) Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2) — 24.4; 15.6; 14.6; 9.8 Titer

Primary: Number of Participants With Maximum Systemic Reaction After Vaccination 1 — 16; 15; 9; 6 Participants

Primary: Safety — 22; 3; 0; 18 percentage of participants

Primary: Number of Participants in the CD4 Less Than 200/mL Stratum With 4-Fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza…

Primary: Number of Subjects With Influenza-like Clinical Illness and Laboratory Confirmed Infection Post Challenge With a Homologous A Strain Influenza Virus — 17; 19; 15…

Primary: Number of Participants Who Shed Virus — 0 participants

Primary: Number of Participants Reporting Solicited Subjective Local Reactions After First Vaccination — 15; 21; 26; 37 Participants

Primary: Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain. — 589.8; 933.1 Titers

Primary: Determination of Immune Response to Vaccination. — 45 participants

Primary: Percentage of Participants With Serious Adverse Events (SAEs) Attributed To Vaccination — 1; 0; 3; 0 percentage of participants

Primary: Area Under the Curve of Virus Load — -2081.98; 18,973.90; 15,944.09; 12,201.14 mins*Eq log10 TCID50/mL

Primary: Number of Subjects With Solicited Local Symptoms — 212; 16; 39; 3 Participants

Primary: Number of Participants Age 6 Months to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza…

Primary: Number of Participants Reporting Solicited Local Reactions Based on the Functional Grading Scale After the First Vaccination — 29; 53; 62; 95 Participants

Primary: Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days…

Primary: The Number of Participants Who Had at Least One Adverse Event (AE) — 113; 0; 7; 6 participants

Primary: Number Subjects Who Responded to Two or Three Vaccinations of the MF59-H5N1 Influenza Vaccine — 0; 1; 0; 2 Subjects

Primary: The Number of Participants Who Had at Least One Adverse Event (AE) — 118; 11; 8; 0 Participants

Primary: Number of Subjects Seropositive for Haemagglutination Inhibition (HI) Antibodies Against the A/California Virus Strain — 91; 48; 168; 75 Participants

Primary: Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies — 58 Participants

Primary: Number of Participants Who Shed Virus — 0 participants

Primary: Viral Copy Number in 30-minute Exhaled Breath Sample — 38,000; 12,000 Fine aerosol RNA copy number

Primary: Number of Seroconverted (SCR) Subjects for Hemagglutination Inhibition (HI) Antibodies — 63; 53 Participants

Primary: Number of Participants With Fever Post Dose 1 (Days 1-8), Defined as an Oral Temperature ≥ 101°F (38.3°C). — 0; 0 Participants

Primary: Antibody Responses After the First and Second Vaccinations — 19; 9; 15; 19 Percentages of Subjects

Primary: Solicted Adverse Events — 8; 12; 13; 14 participants

Primary: Number of Subjects Boosted at Month 12 With Haemagglutinin-inhibition (HI) Antibody Concentrations Above the Cut-off Value — 178 Participants

Primary: Number of Seroconverted (SCR) Subjects for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California/7/2009 (H1N1) Virus Strain — 60; 44 Participants